Sanadelaslam S A El-Hddad

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 4

Top Topics

Breast Cancer Cells

Molecular Docking

Protein Protein

Coronavirus Disease

Top Venues

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Sanadelaslam S A El-Hddad, Mohamed H Sobhy, Ahmed El-Morsy, Nabil A Shoman, Khaled El-Adl
Quinazolines and thiazolidine-2,4-dions as SARS-CoV-2 inhibitors: repurposing, in silico molecular docking and dynamics simulation. RSC advances 14 (19) (2024)
Sanadelaslam S A El-Hddad, Mohamed H Sobhy, Ahmed El-Morsy, Nabil A Shoman, Khaled El-Adl
Quinazolines and thiazolidine-2,4-dions as SARS-CoV-2 inhibitors: repurposing, in silico molecular docking and dynamics simulation. RSC advances 14 (19) (2024)
Kurls E Anwer, Sanadelaslam S A El-Hddad, Nour E A Abd El-Sattar, Ahmed El-Morsy, Fathalla Khedr, Samy Mohamady, Doaa E Keshek, Samir A Salama, Khaled El-Adl, Noura S Hanafy
Five and six membered heterocyclic rings endowed with azobenzene as dual EGFR T790M and VEGFR-2 inhibitors: design, synthesis, in silico ADMET profile, molecular docking, dynamic simulation and anticancer evaluations. RSC advances 13 (50) (2023)
Mohamed Abdelwahab Abdelgawad, Khaled El-Adl, Sanadelaslam S A El-Hddad, Mostafa M Elhady, Nashwa M Saleh, Mohamed M Khalifa, Fathalla Khedr, Mohamed Alswah, AbdEIAziz A Nayl, Mohammed M Ghoneim, Nour E A Abd El-Sattar
Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARγ Agonists. Pharmaceuticals (Basel, Switzerland) 15 (2) (2022)